Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe9

The companies enter into a…

Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD

Minoryx‘s Marketing Authorization Application for…

Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy

Minoryx raises €51 million to…

Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021

Presentation highlights reduction in cerebral…

Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal

Minoryx publishes mechanism of action…

Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting

Minoryx Phase 2/3 ‘ADVANCE’ study…

Minoryx Therapeutics in the news

Minoryx Therapeutics in the news

Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN)

Minoryx presents topline results from…

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia

Minoryx’s clinical candidate leriglitazone shows…

Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal

Minoryx’s preclinical data for leriglitazone…